Literature DB >> 1438794

Experimental therapeutic studies with miltefosine in rats and mice.

P Hilgard1, J Stekar, R Voegeli, J H Harleman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1438794     DOI： 10.1159/000420837

Source DB:  PubMed          Journal:  Prog Exp Tumor Res        ISSN： 0079-6263


× No keyword cloud information.
  7 in total

1.  Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid.

Authors:  Stefan R Vink; Jan H M Schellens; Wim J van Blitterswijk; Marcel Verheij
Journal:  Invest New Drugs       Date:  2005-08       Impact factor: 3.850

2.  [Spectrographic studies on the radioresistance of Miltex and miltefosine].

Authors:  G Bollmann; H Paukisch; E Bothe; W Strate; G Gademann
Journal:  Strahlenther Onkol       Date:  1997-04       Impact factor: 3.621

Review 3.  Alkylphosphocholines: a new class of membrane-active anticancer agents.

Authors:  P Hilgard; T Klenner; J Stekar; C Unger
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  Erufosine suppresses breast cancer in vitro and in vivo for its activity on PI3K, c-Raf and Akt proteins.

Authors:  Ilina K Dineva; Maya M Zaharieva; Spiro M Konstantinov; Hansjörg Eibl; Martin R Berger
Journal:  J Cancer Res Clin Oncol       Date:  2012-06-30       Impact factor: 4.553

5.  Distribution of hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine in rat tissues during steady-state treatment.

Authors:  N Marschner; J Kötting; H Eibl; C Unger
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  Investigations on the cellular uptake of hexadecylphosphocholine.

Authors:  E A Fleer; D Berkovic; H Eibl; C Unger
Journal:  Lipids       Date:  1993-08       Impact factor: 1.880

Review 7.  The Potential of Novel Lipid Agents for the Treatment of Chemotherapy-Resistant Human Epithelial Ovarian Cancer.

Authors:  Mark W Nachtigal; Alon D Altman; Rajat Arora; Frank Schweizer; Gilbert Arthur
Journal:  Cancers (Basel)       Date:  2022-07-07       Impact factor: 6.575
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.